Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ng on November 16, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 336156. A replay of the webcast will also be available on the corporate website for one month, through December 6, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union, Switzerland, Norway, Iceland, Liechtenstein and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinic
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asia-Pacific ... Analytics market in Asia-Pacific with analysis and forecast of ... million in 2014 to $208 million by 2019, at ... 2014 to 2019. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... have devised a way to squeeze light into tighter ... new technology in the fields of optical communications, miniature ... in passing light through gaps 200 nanometers wide, about ... hair. A group of UC Berkeley researchers led by ...
... 30 Nektar,Therapeutics (Nasdaq: NKTR ) will announce ... 2008 on Wednesday, August 6, 2008, after the,close of ... will host a conference call to review the results,beginning ... (PT)., The press release and a live audio-only ...
... SAN DIEGO, July 30 Neurocrine Biosciences,Inc. (Nasdaq: NBIX ... 30, 2008. For the second quarter of 2008, the Company ... compared with a net loss of,$26.4 million, or $(0.69) per ... the Company reported a net loss of $42.0 million, or ...
Cached Biology Technology:New technique to compress light could open doors for optical communications 2New technique to compress light could open doors for optical communications 3Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2Neurocrine Biosciences Reports Second Quarter 2008 Results 2Neurocrine Biosciences Reports Second Quarter 2008 Results 3Neurocrine Biosciences Reports Second Quarter 2008 Results 4Neurocrine Biosciences Reports Second Quarter 2008 Results 5Neurocrine Biosciences Reports Second Quarter 2008 Results 6Neurocrine Biosciences Reports Second Quarter 2008 Results 7Neurocrine Biosciences Reports Second Quarter 2008 Results 8Neurocrine Biosciences Reports Second Quarter 2008 Results 9
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... technical developments, and we will be increasingly moulded and changed ... future if we know what awaits us. So how can ... Applications Trends can provide sound assistance. It contains ... clear descriptions of all the main fields of technology. ...
... Sobrado, assistant professor of biochemistry ( http://www.biochem.vt.edu/faculty.php?lname=Sobrado&view=yes ) ... Tech, has received a Ralph E. Powe Junior ... that are essential for infection in two important ... presents the Powe award to faculty members who ...
... years ago: animals don,t pick their mates by pure chance ... factors. After decades of examining his work, experts agree that ... big question is, "What have we learned since then?" asks ... Adam Jones, an evolutional biologist who has studied Darwin,s work ...
Cached Biology News:Technology guide: Principles -- applications -- trends 2Powe Award supports research on how enzymes enable the pathogenicity of 2 human disease organisms 2Why do we choose our mates? Ask Charles Darwin, prof says 2
...
BD IMagnet 1 each...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: